Fda Quotations
Fda Quotes from:
-
Approve Quotes
When the FDA forces an old drug off the market, patients have very little say in the matter. Patients have even less of a say when the FDA chooses not to approve a new drug. Instead, we are supposed to rely on the FDA's judgment and be grateful. But can the FDA really make a choice that is appropriate for everyone? Of course not.
-
Applaud Quotes
We applaud the FDA for defining what whole grain is. Unfortunately, the FDA has not defined any claims concerning the grain content of foods. Consumers should continue to check labels. Grains such as wheat, rice, oats or corn must be described as 'whole' in the list of ingredients to be considered a significant source of whole grain and also should be one of the first three ingredients listed.
-
Advanced Quotes
We are pleased with our performance in 2005. The year was highlighted by the filing of the new drug application on NRP104, our lead compound under development, for the treatment of Attention Deficit Hyperactivity Disorder in pediatric populations. We believe that this advancement together with the progress on our other pipeline products positions us well for future growth. Looking forward, we anticipate receiving approval from the FDA on NRP104 in the second half of 2006 and making IND filings on NRP409 and NRP388, the two most advanced candidates in our preclinical pipeline, by the end of the second quarter of 2006. In addition, we plan to continue to develop NRP290, our second most advanced compound, and other drug products in our research pipeline.
-
Biased Quotes
Most studies submitted to the FDA have been conducted by the manufacturers of implants who obviously have a vested interested and whose findings are frequently biased and misleading. We must reform this heavy reliance on industry, which interferes with sound scientific decision-making by the FDA.
-
Closely Quotes
Phase 2 studies are typically well controlled and closely monitored and may involve up to several hundred patients. At the conclusion of these studies, FDA (Food and Drug Administration) and the sponsor usually meet to determine how the drug's development should be studied in Phase 3 and how to design and conduct further trials.
-
Applaud Quotes
I applaud Congress for the passage of FALCPA. Chairman Joe Barton and Ranking Member John D. Dingell in the House, Energy and Commerce Committee were instrumental in moving this bipartisan legislation forward. Representative Nita Lowey was the original sponsor of the legislation. FDA also applauds the dedication and leadership of the legislation's sponsors in the Senate, which include Senators Judd Gregg and Edward Kennedy.
-
Abortion Quotes
If supporters of RU-486 believe the FDA followed the law in approving RU-486 for abortion, they should have nothing to fear from the proposed review. But if the FDA bent the rules to expedite approval of RU-486, the agency clearly valued the 'health' of the abortion industry over women's health and should be brought to account.
-
Benefits Quotes
We think that if your company complies with the FDA processes, if you bring forward the benefits and risks of your drug, and let your information be judged through a process with highly trained scientists, you should not be second-guessed by state courts that don't have the same scientific knowledge.
-
Approved Quotes
We've got to do a better job of segregating those commodities to make sure that ... we basically protect people from things that haven't been approved, ... The FDA is monitoring the situation very closely, very carefully. I don't think there is any public health and safety issue here, but the fact is the product has not been approved for human consumption. It should not be served.
-
Agency Quotes
While I was pleased to receive assurances that the agency will, in the coming weeks, deliver a long overdue decision on Plan B, concerns about Dr. Crawford's leadership remain, ... I have been continually concerned during Dr. Crawford's tenure that FDA hasn't shown the independence and adherence to science necessary to inspire public confidence.
-
Advise Quotes
FDA is conducting a thorough evaluation of the safety profile for this drug in light of the recent publications. We're working to evaluate the potential risks and determine whether there is a need for further action. In the meantime, we advise providers to carefully assess the benefits and risks of the drug for their patients.
-
Allowance Quotes
FDA allowance to export the cartridges made at our San Diego plant was the final regulatory hurdle we needed to overcome in order to start treating patients in our pivotal clinical trial in China. Personnel are now being trained and cartridges manufactured so we can begin patient treatment early in 2006.